Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Enzyme may hold the key to fighting deadly parasite diseases
African tsetse fly
Enzyme could hold the key to combatting deadly parasite diseases such as African sleeping sickness, spread by the tsetse fly.

Fresh discoveries could enable the design of treatments to tackle diseases without harm to the patient

Researchers at the University of Edinburgh believe that an enzyme, found in all living things, could hold the key to combating deadly parasite diseases such as sleeping sickness.

A study into the enzyme, which helps cells convert nutrients into energy, has revealed that it is activated in various ways in different species.

The researchers say that this finding creates an opportunity to design drugs that inhibit activity of the enzyme in species that cause infection. Blocking the enzyme effectively kills the parasite, but does not affect the same enzyme in the patient.

It is hoped that the findings will lead to new treatments for diseases spread by parasites that affect millions of people in the developing world.

It is also anticipated that the discovery will ultimately help fight a variety of healthcare problems, including antibiotic resistance and some cancers.

A range of analytical techniques were employed to learn how the enzyme - pyruvate kinase - functions in bacteria, mammals and parasites.

The scientists discovered that the enzyme becomes active in all species in a similar way. A small sugar molecule binds to the enzyme to begin the process of nutrient absorption. However, each species has a unique mechanism for activating the enzyme, which provides opportunities to design drugs that block its activity in individual species.

Professor Malcolm Walkinshaw, who led the study, said: "With this discovery, we've found an Achilles heel for sleeping sickness and many other conditions. Fresh discoveries about this key enzyme - pyruvate kinase - could enable the design of treatments to tackle diseases without harm to the patient." 

Image (C) David Dennis

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.